Sakar Healthcare P/E Ratio
Sakar Healthcare (SAKAR) P/E ratio is 70.13 (High), EPS (TTM) ₹13.70, current price ₹1179.80 on NSE vs historical average P/E of 30.42 (100.0th percentile) — Very High - High growth expectations or significantly overvalued. Also explore SAKAR share price data to track price trends across different timeframes.
Current Valuation Metrics
Valuation Signal
Sector Context
Earnings Breakdown (TTM)
SAKAR P/E Ratio — Valuation Signal & Historical Context
Sakar Healthcare P/E 70.13 vs historical average 30.42, range 30.42–30.42 — signal: Overvalued.
- Stock appears overvalued with PE of 70.13, suggesting caution for new investments
- Current PE is 130.5% above historical average
- Trading at premium to sector average PE of 56.73
Sakar Healthcare P/E Ratio Historical Trend
SAKAR annual price-to-earnings ratio — 1 years, EPS and year-end price. Current P/E 70.13 vs historical average 30.42. For live price, revenue and the complete fundamental profile, see Sakar Healthcare stock price NSE.
SAKAR Historical P/E Ratio — EPS, Year-End Price & Valuation
Sakar Healthcare annual P/E ratio, EPS (₹), year-end price and valuation category on NSE.
| Year | P/E Ratio | EPS (₹) | Year-end Price (₹) | Exchange | Valuation |
|---|---|---|---|---|---|
| 2025 | 30.42 | 11.39 | ₹346.45 | NSE | High |
SAKAR vs Healthcare Peers — P/E Ratio Comparison
Sakar Healthcare P/E 70.13 vs Healthcare average 56.73, median 31.66 — range 1.99–747.21.
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 1.99 | ₹66 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Colinz Laboratories | COLINZ | 3.27 | ₹9 | Low |
| Phaarmasia | PHRMASI | 3.41 | ₹59 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.03 | ₹6,361 | Low |
| Dipna Pharmachem | DPL | 4.65 | ₹12 | Low |
| JFL Life Sciences | JFLLIFE | 4.95 | ₹67 | Low |
| Shelter Pharma | SHELTER | 5.71 | ₹56 | Low |
| GKB Ophthalmics | GKB | 5.9 | ₹33 | Low |
| Kabra Drugs | KABRADG | 6.29 | ₹49 | Low |